Immunome (IMNM) CMO exercises 55K options and sells 55K shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Immunome Inc. Chief Medical Officer Robert Lechleider reported option exercises and share sales in Immunome Inc. common stock. On July 2, 2026, he exercised employee stock options covering 55,000 shares at an exercise price of $8.73 per share, converting derivative awards into common stock.
On the same date, he sold a total of 55,000 shares in multiple open-market transactions at prices around $21.95–$23.44 per share under a pre-arranged Rule 10b5-1 trading plan adopted on March 26, 2026. Following these transactions, he holds 70,805 shares of common stock directly and 290,000 remaining employee stock options that are scheduled to vest over time and expire in 2033.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 55,000 shares ($1,244,331)
Net Sell
5 txns
Insider
Lechleider Robert
Role
Chief Medical Officer
Sold
55,000 shs ($1.24M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 55,000 | $0.00 | -- |
| Exercise | Common Stock | 55,000 | $8.73 | $480K |
| Sale | Common Stock | 22,714 | $21.95 | $499K |
| Sale | Common Stock | 16,214 | $22.76 | $369K |
| Sale | Common Stock | 16,072 | $23.44 | $377K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 290,000 shares (Direct, null);
Common Stock — 70,805 shares (Direct, null)
Footnotes (1)
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026. The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.
Key Figures
Shares sold: 55,000 shares
Sale prices: $21.95–$23.44 per share
Options exercised: 55,000 shares
+5 more
8 metrics
Shares sold
55,000 shares
Total common shares sold on July 2, 2026
Sale prices
$21.95–$23.44 per share
Weighted average prices across reported sale tranches
Options exercised
55,000 shares
Employee stock options converted to common stock
Option exercise price
$8.73 per share
Strike price for exercised employee stock options
Shares held after
70,805 shares
Common stock directly owned post-transactions
Options remaining
290,000 options
Employee stock options outstanding after the exercise
Option vesting start
25% on October 16, 2024
Initial vesting milestone for the reported option grant
Option expiration
October 26, 2033
Expiration date for the reported option grant
Key Terms
Rule 10b5-1 trading plan, open-market sale, Employee Stock Option (right to buy), weighted average sale price, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
open-market sale financial
"transaction_action: "open-market sale" for common stock dispositions on July 2, 2026."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Employee Stock Option (right to buy) financial
"security_title: "Employee Stock Option (right to buy)" for the derivative transaction exercised on July 2, 2026."
weighted average sale price financial
"The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive."
derivative exercise/conversion financial
"transaction_action: "derivative exercise/conversion" describing the option exercise coded as "M"."
FAQ
What insider transactions did Immunome (IMNM) report for Robert Lechleider?
Immunome Chief Medical Officer Robert Lechleider exercised options for 55,000 shares and sold 55,000 shares of common stock on July 2, 2026. These open-market sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted earlier in March 2026.
What stock options did Immunome (IMNM) CMO exercise in this Form 4?
The CMO exercised employee stock options covering 55,000 Immunome shares at an exercise price of $8.73 per share. These options relate to a grant where 25% vested on October 16, 2024, with the remaining options vesting monthly over three years until expiration in 2033.
Does Immunome (IMNM) CMO still hold stock options after the Form 4 transactions?
Yes. Following the July 2, 2026 activity, he holds 290,000 employee stock options. These options carry an exercise price of $8.73 per share for the reported grant and are scheduled to continue vesting monthly, with final expiration disclosed as October 26, 2033.
Were Immunome (IMNM) insider sales by the CMO pre-planned?
The Form 4 states the CMO’s sales were executed under a Rule 10b5-1 trading plan adopted on March 26, 2026. Such plans pre-schedule trades, meaning the timing of these sales followed the plan’s instructions rather than discretionary day-to-day trading decisions.